IMMUNE CHECK ACTIVATORS MARKET ANALYSIS
Key Developments
Research and development activities related to immune check activators is expected to boost the market growth. For instance, in April 2019, researchers from Medical University of Lublin assessed the factors that impact the efficiency of immunotherapy with anti-PD-L1 antibodies in non-small cell lung cancer patients. The team suggested that additional markers are needed to more accurately determine the patients that will benefit from immunotherapy treatment.
In July 2019, researchers from Medical College of Wisconsin conducted a study to identify the roles of Activator Protein (AP)-1 in the regulation of anti-tumor immune responses. The team found that AP-1 components transcriptionally induced the expression of genes encoding for co-inhibitory immune checkpoints (PD-1, PD-L1) via binding on the enhancer regions of the respective gene promoter.
In August 2019, researchers from University of Bourgogne Franche-Comté highlighted the ambivalent effects of signal transducer and activator of transcription 3 (STAT3) on the antitumoral immune response.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
